Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Sazdanoff Catherine

(Last) (First) (Middle)


(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy) (4) 01/11/2025 Common Shares 1,061 6.33(1) D
Director Stock Option (Right to Buy) 07/01/2019(3) 07/01/2024 Common Shares 3,030 8.35(2) D
Explanation of Responses:
1. Converted from Canadian exercise price of C$8.25 using an exchange rate of C$1.3039 = US$1.00.
2. Converted from Canadian exercise price of C$10.89 using an exchange rate of C$1.3039 = US$1.00.
3. 1,344 of the options have vested. The remaining 1,686 options will vest monthly through July 1, 2022.
4. The options were granted on January 12, 2020, and will fully vest on the earlier of January 12, 2021, or immediately prior to the Issuer's next annual general meeting.
Exhibit 24.1 Power of Attorney
/s/ Catherine Sazdanoff 11/12/2020
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Know all by these presents, that the undersigned hereby constitutes and appoints Bruce S. Colwill and
Rocio Lebolo, each acting alone, as the undersigned's true and lawful attorney-in-fact to:
(1)	execute for and on behalf of the undersigned, in the undersigned's capacity as an officer,
director and/or 10% shareholder of InMed Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5
(including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934
and the rules and regulations thereunder and any Form ID, Uniform Application for Access Codes to File
on Edgar, or Update Passphrase Form;
(2)	do and perform any and all acts for and on behalf of the undersigned which may be necessary or
desirable to complete and execute any such Forms 3, 4 or 5, Form ID or Update Passphrase Form and timely
file such forms (including amendments thereto) and application with the United States Securities and
Exchange Commission and any stock exchange or similar authority; and
(3) 	take any other action of any type whatsoever in connection with the foregoing which, in the
opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required
by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms
and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform
any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any
of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might
or could do if personally present, with full power of substitution or revocation, hereby ratifying and
confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.
The undersigned agrees that each such attorney-in-fact herein may rely entirely on information furnished
orally or in writing by the undersigned to such attorney-in-fact. The undersigned also agrees to
indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims,
damages or liabilities (or actions in these respects) that arise out of or are based upon any untrue
statements or omission of necessary facts in the information provided by the undersigned to such
attorney-in fact for purposes of executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including
amendments thereto), Form ID or Update Passphrase Form and agrees to reimburse the Company and such
attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss, claim, damage, liability or action.
This Power of Attorney supersedes any power of attorney previously executed by the undersigned regarding
the purposes outlined in the first paragraph hereof ("Prior Powers of Attorney"), and the authority of
the attorneys-in-fact named in any Prior Powers of Attorney is hereby revoked.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required
to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities
issued by the Company, unless earlier (a) revoked by the undersigned in a signed writing delivered to
the foregoing attorneys-in-fact or (b) superseded by a new power of attorney regarding the purposes
outlined in the first paragraph hereof dated as of a later date.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day
of November, 2020.

/s/ Catherine Sazdanoff